FDA approves a new treatment Pill for Type 2 Diabetes

FDA approves a new treatment Pill for Type 2 Diabetes

Diabetes type 2 is one of the fastest-growing diseases in the world. It is a condition in which the pancreas is not able to make sufficient insulin for the body. It results in having low blood sugar levels. The U.S. Food and Drug Administration has recently approved a game-changing new treatment pill for type 2 Diabetes. It cab reduce the blood sugar in adult diabetic patients along with a healthy, sugar-free diet.

Click here to read the official Press Release by FDA. 

The name of this new anti-diabetic drug is Rybelsus(semaglutide) which is the first-ever pill formulated from glucagon-like peptide (GLP-1) which is a non-insulin treatment pill for type 2 diabetes patients. This pill was previously available in injectable form only. This pill doesn’t need an injection instead it requires an oral consumption.

How it reduces blood sugar?

GLP-1 is a type of hormone that is common in people with low blood sugar i.e. diabetic patients. This drug works by slowing down the digestion and controlling liver to prevent making an excess of sugar. This is to prevent the accumulation of excess sugar in the blood thus enabling the pancreas to make insulin.

The clinical trials of Rybelsus show that it is able to reduce the high blood sugar. Rybelsus was checked as individual therapy and in combination with other medicines such as metformin, sulfonylureas, and sodium-glucose co-transporter-2 (SGLT-2) inhibitors. In placebo trials, Rybelsus as n individual therapy has significant results.

Also read- The diabetes risk increases in women with extra belly fat

The duration of clinical trials was 26 weeks. After passing 26 weeks, an analysis of the study participants show that 77% of them taking 14 mg of Rybelsus have 7% low HbA1C level. This HbA1C test indicates the blood sugar of a person.

Rybelsus comes with warnings

Rybelsus, is manufactured by a pharmaceutical company called Novo Nordisk. Despite its approval from the FDA, it is not the first line of treatment for diabetic people for its potential risks.

The research also indicates the risks of using Rybelsus, which include thyroid tumor production. If the patient has an existing thyroid condition or thyroid cancer, this drug is not a part of his diabetes treatment.

Rybelsus can also cause pancreatitis, which is a medical condition showing inflammation of the pancreas. It may also lead to retinal damage- diabetic retinopathy, low blood sugar-hypoglycemia or acute kidney problems and reactions. The risk is higher for Rybelsus and sulfonylureas or Rybelsus and insulin combination.

FDA recommends using Rybelsus at least 30 minutes before the first meal or beverage of the day. The best is to consume it with 4oz of water. Remember that Rybelsus works on digestion and slows it. So it is necessary to discuss all other medicines that a person may be taking with the doctor. Using it with any other medicine may cause nausea, diarrhea, constipation, indigestion, dizziness, loss of appetite, sleep irregularity, etc.



The author is a Medical Microbiologist and healthcare writer. She is a post-graduate of Medical Microbiology and Immunology. She covers all content on health and wellness including weight loss, nutrition, and general health. Twitter @Areeba94789300

Leave a Reply
Your email address will not be published. *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

error: Content is protected !!